Silence Therapeutics Files 8-K
Ticker: SLNCF · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 8-K |
| Filed Date | Oct 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Silence Therapeutics filed an 8-K on 10/23/25. Standard disclosure, check filing for details.
AI Summary
On October 23, 2025, Silence Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating a routine update or disclosure without specifying any major transactions or events. The company is incorporated in England and Wales and its principal executive offices are located in London.
Why It Matters
This 8-K filing from Silence Therapeutics plc indicates a standard disclosure event, providing updates on company events and financial statements. Investors should review the full filing for specific details.
Risk Assessment
Risk Level: low — The filing appears to be a routine 8-K with no immediately apparent material adverse events or significant financial disclosures.
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- October 23, 2025 (date) — Date of Report
- England and Wales (jurisdiction) — State or Other Jurisdiction of Incorporation
- London (location) — Address of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The filing is for "Other Events" and "Financial Statements and Exhibits," suggesting a routine disclosure or update.
When was this 8-K report filed?
The report was filed on October 23, 2025.
Where are Silence Therapeutics plc's principal executive offices located?
The principal executive offices are located at 12 Hammersmith Grove, London, United Kingdom, W6 7AP.
What is the company's standard industrial classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
What is the company's telephone number?
The company's telephone number is +44 20 3457 6900.
Filing Stats: 628 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2025-10-23 07:45:25
Filing Documents
- sln-20251023.htm (8-K) — 57KB
- sln-ex99_1.htm (EX-99.1) — 26KB
- 0001193125-25-247692.txt ( ) — 237KB
- sln-20251023.xsd (EX-101.SCH) — 53KB
- sln-20251023_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On October 23, 2025, Silence Therapeutics plc issued a press release announcing completion of enrollment in the SANRECO Phase 2 study of divesiran for the treatment of polycythemia vera (PV). A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference. The information in this Item 2.02 of this Current Report on 8-K, including Exhibits 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
01 Exhibits
Item 9.01 Exhibits. (a) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 99.1 Press Release dated October 23, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Company Name Date: October 23, 2025 By: /s/ Craig Tooman Name: Craig Tooman Title: President and Chief Executive Officer (Principal Executive Officer)